Page 4 - Mc Services News Today

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium...

Shares concerned: Carbios Market concerned: Euronext Growth Paris Clermont-Ferrand , 10 January 2024 . CARBIOS, , a pioneer in the development and industrialization of biological...

Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous09.01.2024 / 14:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Mainz Biomed Provides Year-End Corporate Review 2023 European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Co...

PREVYMIS® now approved in the U.S. and Europe for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R‑])EMA approval triggers a €15 Million Milestone payment to AiCuris and AiCuris is eligible for further milestone p...

Mainz Biomed Provides Year-End Corporate Review 2023...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Study results Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia...

MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg ...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): StudyNewron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide 29.12.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Newron completes enrollment of schizophrenia patie...

MILAN--(BUSINESS WIRE)--Dec 29, 2023--

PRESS RELEASE CARBIOS publishes its second sustainability report and confirms its ambitions to accelerate the circular economy for plastic Clermont-Ferrand , 21 December 2023 . CARBIOS, , a...